Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
320.08M | 156.31M | 98.02M | 295.67M | 88.17M | 150.05M | Gross Profit |
131.99M | -81.37M | -99.23M | 113.59M | -56.80M | -18.29M | EBIT |
53.49M | -159.55M | -179.43M | 42.28M | -117.23M | -70.14M | EBITDA |
72.56M | -145.92M | -161.85M | 44.02M | -114.63M | -63.45M | Net Income Common Stockholders |
-1.53M | -245.76M | -271.51M | -94.70M | -240.13M | -149.14M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
53.05M | 76.11M | 193.36M | 306.92M | 99.87M | 61.81M | Total Assets |
136.40M | 313.91M | 413.56M | 465.96M | 214.51M | 155.34M | Total Debt |
13.36M | 78.01M | 78.43M | 58.29M | 55.73M | 23.39M | Net Debt |
-39.70M | 1.90M | -100.25M | -233.64M | -44.14M | -38.41M | Total Liabilities |
310.95M | 462.30M | 468.46M | 418.05M | 426.01M | 386.67M | Stockholders Equity |
-172.47M | -160.33M | -61.28M | 34.44M | -203.67M | -225.36M |
Cash Flow | Free Cash Flow | ||||
-41.74M | -234.16M | -228.44M | -23.67M | -142.56M | -23.34M | Operating Cash Flow |
12.60M | -224.20M | -175.37M | 10.14M | -139.10M | -18.68M | Investing Cash Flow |
-52.27M | 3.40M | -33.61M | -43.15M | -4.44M | -4.66M | Financing Cash Flow |
194.34M | 119.87M | 95.83M | 225.26M | 183.85M | 31.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $9.77B | 41.86 | 19.71% | ― | 52.97% | ― | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
47 Neutral | $2.07B | ― | -600.68% | ― | -98.62% | -86.21% | |
45 Neutral | $1.58B | ― | 18.68% | ― | 36.00% | 63.50% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
43 Neutral | $1.41B | ― | -26.84% | ― | 1.99% | 15.95% | |
38 Underperform | $48.09M | ― | 260.68% | ― | 59.00% | 32.67% |
Agenus Inc. has secured a $22 million mortgage to bolster its cash reserves and support strategic operational realignment, focusing on its promising immunotherapy candidates, botensilimab and balstilimab, for colorectal cancer. The loan, facilitated by L&L Capital, involves a two-year term with interest payable in cash and stock. Agenus aims to significantly cut costs and transform its manufacturing operations while advancing its clinical programs, positioning itself for growth and innovation in cancer treatment.